Navigation Links
Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Date:6/27/2011

risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that the proposed Transdel transaction will be completed; that our stockholder's equity can be increased and maintained to a sufficient level to satisfy ongoing compliance with the requirements of our listing stock exchange; that Ketotransdel can be successfully developed to result in an FDA Section 505(b)(2) registered product in the United States; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the U.S. Food and Drug Administration (the "FDA") will grant marketing clearance of Ketotransdel or other product candidates or that we or a partner can successfully introduce these or additional products into topical NSAID markets in the U.S. or elsewhere; that Ketotransdel or other product candidates will prove to be sufficiently safe and effective; that Ketotransdel or other product candidates are seen as suitable or preferred products compared to other FDA-approved products that currently are or will be on the market; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... July 24, 2014  Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the first ... quarter overview: , Revenues of $47.5 million, up ... EPS of $0.21, up 50% over last year,s comparable ... revenues of $7.2 million, up 20% over last year,s ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... One of the most difficult-to-remove tumors located deep in ... the work of one Los Angeles surgeon. Hrayr Shahinian ... Los Angeles, has developed a minimally invasive approach to removing ... procedure is expected to replace the more invasive open brain ...
... 18 For some people with ongoing or chronic pain, ... difference between disability and the ability to function at near-normal ... surgery or injury, sound pain management with opioids can speed ... medications and carry risks when they are not used properly. ...
Cached Medicine Technology:Dr. Hrayr Shahinian of the Skull Base Institute Develops Revolutionary Endoscopic Procedure 2Opioid Education Lags as Abuse Climbs 2Opioid Education Lags as Abuse Climbs 3
(Date:7/25/2014)... York, US (PRWEB) July 25, 2014 ... global provider of technology-enabled services for the financial, ... that its virtual data room business, Merrill DataSite, ... the Year” presented by GrowthBusiness at the M&A ... Awards recognize the achievements of entrepreneurs, management teams, ...
(Date:7/25/2014)... A new study of participants in the National Lung ... in Cancer , found evidence that men and women ... abnormal finding on a lung cancer screening test did not ... those who were screened and found to be cancer-free. ... “We expected that participants with an abnormal finding would be ...
(Date:7/25/2014)... Hastings and Hastings, a ... with regard to personal injury claims, announces free initial ... of legal services for those that have been injured ... or corporation. Free initial consultation services gives clients’ greater ... potential personal injury claim . It also offers ...
(Date:7/25/2014)... (HealthDay --, Treatment for lymphoma may lower men,s fertility, ... lymphoma, which are cancers of the body,s white blood ... their reproductive years. For men, treatment for these cancers ... regain their fertility within two years of treatment, the ... possibility of this significant side effect before treatment begins. ...
(Date:7/25/2014)... Parkulture is proud to announce ... instructor, Jared “JJ” Woods, will be competing on NBC’s ... Warrior. The show will premiere on local affiliates this ... on the new Esquire Network on Tuesday, July 29th ... been balancing careers as a professional stuntman for film ...
Breaking Medicine News(10 mins):Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3
... catches on with yet another research study which says that eating ... in children. // , ,Researchers found that kids who ate ... have asthma attacks and wheezing. Other takeaway food and fizzy drinks ... ate at least one hamburger a week were 75 percent more ...
... the walls of a patient's room have been found ... and rheumatic complaints, a study says.//,A study group attached ... in medicated rooms were cured in shorter less time ... involved 36 patients, of whom 19 were kept in ...
... new medical device that is believed to allow bone ... quantities to permit far more research and allow faster ... difficulties in the growth and transplantation of stem cells. ... mimic conditions encountered by adult stem cells within the ...
... to tackle the issue of vaccination against Japanese Encephalitis ... country where the vaccine is available in a sizeable ... in Uttar Pradesh and Bihar has prompted the initiative ... also planned for detailed discussions with the Chinese minister ...
... Justice Silber is to give his verdict over the right ... consent or knowledge. The case which has been brought by ... pregnant. // ,The family planning association told the ... about contraception use and abortion does not match the views ...
... which could eventually lead to a practical and cost effective ... US National Cancer Institute have genetically modified bacteria living in ... // ,Most HIV transmission occurs on the surfaces ... with a layer of bacteria. ,The researchers have ...
Cached Medicine News:Health News:A warning for children consuming hamburgers: Asthma 2Health News:Now medicated coir to cure ailments 2Health News:Perfusion bioreactor could enhance stem cell research and application in the future 2Health News:Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations 2Health News:Genetically modified bacteria to combat HIV 2
... BRO-YP2 is Fujinon's pediatric ... outside diameter allows for ... The standard 2.0mm channel ... accessory passage in all ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
Slim bronchoscope designed for paediatric applications....
Medicine Products: